Table 1.
R1 | R2 | X | R3 | R4 | R5 | R6 | Surrogate eIF2α @ μM | IC50b [μM] | cLogP | tR [min] | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.25 | 5 | |||||||||||
3a | H | H | C | CF3 | CF3 | H | H | 3.23±0.18 | 10.16±0.52 | 0.54±0.1 | 6.41 | 19.7 |
3′a | H | H | C | OCF3 | CF3 | H | H | 3.37±0.61 | 10.08±0.51 | 0.82±0.2 | 6.48 | 20.2 |
Substitution of electron withdrawing groups on the 4-aryloxycyclohexyl moiety bearing a N-(3-trifluromethyl)phenyl ring | ||||||||||||
3a | CONH2 | H | C | CF3 | CF3 | H | H | 0.91±0.03 | 1.49±0.01 | 2.76±0.4 | 5.07 | 16.3 |
3b | H | CONH2 | C | CF3 | CF3 | H | H | 0.79±0.03 | 1.12±0.02 | 3.36±0.5 | 4.87 | 15.6 |
3c | NHCOCH3 | H | C | CF3 | CF3 | H | H | 0.84±0.12 | 3.9±0.02 | 1.46±0.4 | 5.17 | 17.5 |
3d | NO2 | H | C | CF3 | CF3 | H | H | 0.96±0.02 | 3.28±0.12 | 5.51±1.4 | 6.01 | 19.2 |
3h | – | H | N | CF3 | CF3 | H | H | 1.02±0.10 | 6.11±0.11 | 1.57±0.2 | 5.66 | 19.1 |
3i | CN | H | C | CF3 | CF3 | H | H | 1.01±0.07 | 6.3±0.18 | 1.47±0.3 | 6.00 | 18.8 |
3j | H | H | C | CN | CF3 | H | H | 0.92±0.06 | 3.23±0.23 | 6.06±1.0 | 4.84 | 17.4 |
p- CF3 vs p-CN substituents on the phenylcyclohexyl moiety | ||||||||||||
3e | H | H | C | CF3 | CF3 | H | CF3 | 8.58±0.13 | 30.72±0.77 | 0.45±0.03 | 7.48 | 21.7 |
3f | H | H | C | CF3 | CN | H | H | 0.96±0.08 | 7±0.12 | 0.94±0.1 | 5.13 | 17.9 |
3g | H | H | C | CF3 | H | CN | H | 3.38±0.21 | 11.63±0.05 | 0.49±0.02 | 5.13 | 17.8 |
3k | H | H | C | CN | H | CN | H | 1.03±0.01 | 1.38±0.13 | 9.03±3.1 | 3.76 | 15.1 |
3l | H | H | C | CN | CN | H | H | 1.01±0.02 | 1.15±0.08 | 8.2±1.2 | 3.76 | 15.2 |
N-phenyl ring bearing nitrile groups | ||||||||||||
3r | H | H | C | CF3 | CN | H | CF3 | 5.65±0.28 | 13.16±1.36 | 0.25±0.02 | 6.20 | 19.9 |
3s | H | H | C | CF3 | CN | CN | H | 5.54±1.34 | 7.75±1.97 | 2.01±0.7 | 4.81 | 18.3 |
3t | H | H | C | CF3 | CN | H | CN | 1.51±0.39 | 2.36±0.14 | 3.68±1.1 | 4.81 | 18.4 |
Substitution of electron withdrawing groups on the 4-aryloxycyclohexyl moiety bearing a N-(3-trifluoromethoxy)phenyl ring | ||||||||||||
3m | CONH2 | H | C | CF3 | OCF3 | H | H | 0.88±0.09 | 5.13±0.02 | 1.53±0.4 | 3.93 | 16.6 |
3n | H | CONH2 | C | CF3 | OCF3 | H | H | 1.04±0.06 | 1.57±0.18 | 3.66±0.9 | 3.73 | 16.0 |
3o | NHCOCH3 | H | C | CF3 | OCF3 | H | H | 0.85±0.06 | 4.31±0.13 | 1.5±0.3 | 4.97 | 17.9 |
3p | H | H | C | OCF3 | OCF3 | H | H | 2.87±0.16 | 10.70±0.19 | 1.45±0.2 | 6.28 | 20.3 |
3q | H | H | C | CF3 | OCF3 | H | H | 5.2±0.08 | 13.6±0.70 | 0.92±0.1 | 6.21 | 20.1 |
para-(4-substituted)phenoxy)phenyl-containing 1,3-diarylureas | ||||||||||||
6a | H | H | C | CF3 | CF3 | H | H | 3.31±0.24 | 8.99±0.1 | 0.44±0.1 | 7.40 | 20.5 |
6b | H | H | C | CF3 | OCF3 | H | H | 2.37±0.03 | 6.73±0.22 | 0.5±0.2 | 7.20 | 20.9 |
Reported previously in Ref. 9.
Concentration that inhibits 50% of human CRL-2813 melanoma cell growth.